Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Anti-Diabetic Effects of Ayanin, a Flavonoid Compound, in STZ/HFD-Induced Diabetic Mice by Upregulating GLUT4 and Suppressing Macrophage-Driven Inflammation in Adipose Tissues

Lv Y., Wu C., Yang W., Wang C., Huang J., Wang J.

Animal Study on Type 2 Diabetes, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Food Sci Nutr (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41509193
PMCID
PMC12778411
DOI
10.1002/fsn3.71429

Abstract (original English)

Insulin resistance, marked by reduced GLUT4 expression in metabolic tissues such as adipose tissue and skeletal muscle, is a key contributor to the pathogenesis of Type 2 diabetes. Therapeutic agents that enhance GLUT4 expression in these tissues have demonstrated potential in the treatment of diabetes. Ayanin (AYN) is a flavonoid found in red wine grapes. This study evaluated the anti-diabetic properties of AYN and investigated its mechanisms. In an in vivo study, the oral administration of AYN to diabetic mice resulted in ameliorated hyperglycemia and glucose tolerance and alleviated lipid dysfunction. The investigation into the underlying mechanisms revealed that AYN activated p-AMPKα, which subsequently enhanced GLUT4 and CPT-1α expression in both adipose and muscle tissues, as well as increased CPT-1α expression in livers. In vitro experiments demonstrated that AYN activated AMPKα, increased GLUT4 expression, and facilitated glucose uptake in 3T3-L1 adipocytes. Additionally, the metabolic dysfunctions related to lipids and glucose in adipocytes triggered inflammatory activation of macrophages within adipose tissue, leading to the exacerbation of insulin resistance and the downregulation of GLUT4 expression. AYN reduced macrophage infiltration and pro-inflammatory mRNA expression in adipose tissues, contributing to the amelioration of diabetes. In vitro results for macropha

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research